Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration-sensitive prostate cancer.

Yang YJ, Kong YY, Li GX, Wang Y, Ye DW, Dai B.

BJU Int. 2018 Dec 7. doi: 10.1111/bju.14642. [Epub ahead of print]

PMID:
30536520
2.

The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.

Guan X, Ma F, Li C, Wu S, Hu S, Huang J, Sun X, Wang J, Luo Y, Cai R, Fan Y, Li Q, Chen S, Zhang P, Li Q, Xu B.

Cancer Commun (Lond). 2019 Jan 3;39(1):1. doi: 10.1186/s40880-018-0346-4.

3.

Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancer.

Russo GI, Bier S, Hennenlotter J, Beger G, Pavlenco L, van de Flierdt J, Hauch S, Maas M, Walz S, Rausch S, Bedke J, Morgia G, Stenzl A, Todenhöfer T.

BJU Int. 2018 Jul;122(1):152-159. doi: 10.1111/bju.14200. Epub 2018 Apr 10.

PMID:
29542849
4.

Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.

Goodman OB Jr, Symanowski JT, Loudyi A, Fink LM, Ward DC, Vogelzang NJ.

Clin Genitourin Cancer. 2011 Sep;9(1):31-8. doi: 10.1016/j.clgc.2011.04.001. Epub 2011 Jun 25.

PMID:
21705286
5.

Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.

Bitting RL, Healy P, Halabi S, George DJ, Goodin M, Armstrong AJ.

Urol Oncol. 2015 Mar;33(3):110.e1-9. doi: 10.1016/j.urolonc.2014.09.002. Epub 2015 Jan 13.

PMID:
25595577
6.

Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer.

Josefsson A, Linder A, Flondell Site D, Canesin G, Stiehm A, Anand A, Bjartell A, Damber JE, Welén K.

Prostate. 2017 Jun;77(8):849-858. doi: 10.1002/pros.23325. Epub 2017 Mar 10.

PMID:
28295408
7.

Classification of circulating tumor cells by epithelial-mesenchymal transition markers.

Wu S, Liu S, Liu Z, Huang J, Pu X, Li J, Yang D, Deng H, Yang N, Xu J.

PLoS One. 2015 Apr 24;10(4):e0123976. doi: 10.1371/journal.pone.0123976. eCollection 2015.

9.

Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.

McDaniel AS, Ferraldeschi R, Krupa R, Landers M, Graf R, Louw J, Jendrisak A, Bales N, Marrinucci D, Zafeiriou Z, Flohr P, Sideris S, Crespo M, Figueiredo I, Mateo J, de Bono JS, Dittamore R, Tomlins SA, Attard G.

BJU Int. 2017 Nov;120(5B):E30-E44. doi: 10.1111/bju.13631. Epub 2016 Sep 18.

10.

Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: A report from the PETRUS prospective study.

Massard C, Oulhen M, Le Moulec S, Auger N, Foulon S, Abou-Lovergne A, Billiot F, Valent A, Marty V, Loriot Y, Fizazi K, Vielh P, Farace F.

Oncotarget. 2016 Aug 23;7(34):55069-55082. doi: 10.18632/oncotarget.10396.

11.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
12.

Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.

Chang K, Kong YY, Dai B, Ye DW, Qu YY, Wang Y, Jia ZW, Li GX.

Oncotarget. 2015 Dec 8;6(39):41825-36. doi: 10.18632/oncotarget.6167.

13.
14.

Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.

Lowes LE, Goodale D, Xia Y, Postenka C, Piaseczny MM, Paczkowski F, Allan AL.

Oncotarget. 2016 Nov 15;7(46):76125-76139. doi: 10.18632/oncotarget.12682.

15.

Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.

De Laere B, Oeyen S, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert E, Van Kerckhove P, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff I, van Dam V, Brouwer A, van Dam PJ, Van den Eynden G, Rutten A, Sleijfer S, Vandebroek J, Van Laere S, Dirix L.

Prostate. 2018 May;78(6):435-445. doi: 10.1002/pros.23488. Epub 2018 Feb 12.

PMID:
29431193
16.

Mesenchymal circulating tumor cells (CTCs) and OCT4 mRNA expression in CTCs for prognosis prediction in patients with non-small-cell lung cancer.

Li S, Chen Q, Li H, Wu Y, Feng J, Yan Y.

Clin Transl Oncol. 2017 Sep;19(9):1147-1153. doi: 10.1007/s12094-017-1652-z. Epub 2017 Apr 3.

PMID:
28374320
17.

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.

Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Datar RH, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Thompson IM Jr, Cote RJ, Vogelzang NJ.

J Clin Oncol. 2014 Apr 10;32(11):1136-42. doi: 10.1200/JCO.2013.51.7417. Epub 2014 Mar 10.

18.

Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients.

Kohli M, Li J, Du M, Hillman DW, Dehm SM, Tan W, Carlson R, Campion MB, Wang L, Wang L, Zhang H, Zhang P, Kilari D, Huang CC, Wang L.

Prostate Cancer Prostatic Dis. 2018 Sep;21(3):411-418. doi: 10.1038/s41391-018-0043-z. Epub 2018 Jun 1.

19.

Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.

Gorges TM, Tinhofer I, Drosch M, Röse L, Zollner TM, Krahn T, von Ahsen O.

BMC Cancer. 2012 May 16;12:178. doi: 10.1186/1471-2407-12-178.

20.

Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.

de la Taille A, Martínez-Piñeiro L, Cabri P, Houchard A, Schalken J; Triptocare LT Study Group.

BJU Int. 2017 Jan;119(1):74-81. doi: 10.1111/bju.13455. Epub 2016 Mar 23.

Supplemental Content

Support Center